Background The association of gout and the so called orthodox cardiovascular risks such as: HTA, diabetes, obesity, hyperlipoproteinemia, metabolic syndrome is well known but poorly understood. Some of the above mentioned comorbidities might increase blood urate levels thus contribute to the development of gout while hyperuricemia (HU) per se might contribute to the development of at least some of the comorbidities. The presence of these conditions in addition to HU and the chronic low grade inflammation evidenced by imaging studies of gout, contributes to the overall excessive CV morbidity and mortality in gouty individuals.
Objectives 1. To estimate 10 year risk of CVD event in the cohort of gouty patients; 2. to assess the health related quality of life (HRQoL) in the same cohort; 3. to correlate the calculated 10 year CVD risk with HRQoL and with the different levels of HU.
Methods Sixty-nine patients with gout (67 men; median age, 59 years; median gout disease duration, 7 years) participated in the cross-sectional study. Relevant data for CVD risk calculation were obtained (gender, age, systolic blood pressure, total cholesterol, HDL diabetes status, CKD, BMI, smoking status). Health status of the patients was assessed by The Short Form (36) Health Survey questionnaire (SF 36). The QRISK®2-2014 web calculator was used to estimate 10-year risk of cardiovascular disease in people with gout. Pearson's and Spearman's correlation coefficients were used to calculate the correlations between data. Statistical analysis was completed using the program SPSS (version 20, Chicago, IL, USA).
Results There were statistically significant association between QRISK score and SF-36PCS (r = -0.295, p=0.014); QRISK score and SF-36 7 (r = -0.247, p=0.040) and QRISK and SF-36 1 (s = -0.347, p=0.003). The level of uric acid and QRISK score showed statistically non-significance correlation. In the same line there were no statistically significance correlations between the level of uric acid and SF-36 scales.
Conclusions 1. The mean value of the 10 year risk of CVD event in the cohort of our gouty patients was 21, 04%. According to that, primary care prophylaxis of CVD event in gouty patients should be taken into consideration. 2. The level of uric acid and QRISK score showed statistically non-significance correlation, but further investigations about this association are preferred. 3. QRISK showed correlation with physical component summery (SF36-PCS). That means that risk factors of CVD can strongly influence and change quality of life in gouty patients.
Richette P, et al. Revisting comorbidities in gout: a cluster analysis.Ann Rheum Dis 2015:74:142-7.
Klooster PM, et al. Comparison of measures of functional disability in patients with gout Rheumatology 2011; 50:709-13.
Todorović M, M.G. Hunink et al. Cost-Effectiveness of Statin Therapy for primary Prevention of Cardiovascular Events in Low-risk Individuals in the UK: How low should we go? Master thesis 2014, Erasmus MC Rotterdam.
Source European Guidelines on CVD Prevention Clinical Practice (2012) European Heart Journal 2012; 33: 1635-1701.
Disclosure of Interest None declared